The 3/8/2024 #JournalClub presented "Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial." The recording is available free to all AAPP members.
Presentation Recording
This is a AAPP member-only resource.
Additional Material
Reference
. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160-170. DOI: 10.1016/S0140-6736(23)02190-6. PubMed PMID: 38104575.